At present, the most promising varieties of pharmaceutical intermediates are mainly as follows:
Nucleoside intermediates. This class of intermediates synthesizes the main anti-HIV drug Zidovudine, made by the United States Glaxo. Made by Wellcome and Bristol-Myers Squibb.
Cardiovascular intermediates. For example, synthetic sartan drugs have become a widely used hypertension treatment drugs because of their advantages of more thorough antihypertensive effect, fewer side effects, long efficacy (stable control of 24-hour blood pressure) and can be used in combination with other sartan drugs. According to statistics, in 2015, the global demand for major sartan drug apis (losartan potassium, olmesartan ester, valsartan, irbesartan, Telmisartan, Candesartan ester) reached 3,300 tons. Total sales were $21.063 billion.
Fluorinated intermediates. Fluorine-containing drugs synthesized by such intermediates have developed rapidly in recent years because of their excellent efficacy, and only 2% of fluorine-containing drugs on the market in 1970 increased to 25% in 2013. Representative products such as fluoroquinolone anti-infective drugs, antidepressant fluoxetine, antifungal drug fluconazole and other drugs accounted for a relatively high proportion of clinical use, among which fluoroquinolone anti-infective drugs accounted for about 15% of the global anti-infective drugs market share. In addition, trifluoroethanol is an important intermediate for the synthesis of anesthetics, while trifluoromethylaniline is an important intermediate for the synthesis of antimalarial drugs, anti-inflammatory and analgesic drugs, anti-prostate drugs and antidepressants, and the market prospect is also very broad.
Heterocyclic intermediates. Represented by pyridine and piperazine, they are mainly used in the synthesis of anti-ulcer drugs, bulk stomach drugs, anti-inflammatory anti-infection drugs, high-efficiency antihypertensive drugs and anti-breast cancer new drugs letrozole.
